Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts

Inflammatory Bowel Disease

The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches

Inflamm Bowel Dis.

Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A

doi: 10.1093/ibd/izaa036.

Inflammatory Bowel Disease

Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: Short-term experience from a single tertiary clinical center

J Crohns Colitis.

Lukas M, Malickova K, Kolar M, Bortlik M, Vasatko M, Machkova N, Hruba V, Duricova D, Lukas M

doi: 10.1093/ecco-jcc/jjaa001.

Inflammatory Bowel Disease

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial

J Intern Med.

Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KE, Tveit KS, Lorentzen M, Berset IP, Fevang BT, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK

doi: 10.1111/joim.12880.

Inflammatory Bowel Disease

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study

Aliment Pharmacol Ther.

Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN

doi: 10.1111/apt.15177.

Inflammatory Bowel Disease

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

Lancet Gastroenterol Hepatol.

Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR

doi: 10.1016/S2468-1253

Inflammatory Bowel Disease

Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort

Eur J Gastroenterol Hepatol.

Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM, Swiss IBD Cohort Study Group

doi: 10.1097/MEG.

Inflammatory Bowel Disease

Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy

J Crohns Colitis.

Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W

doi: 10.1093/ecco-jcc/jjz048.

RECOMMENDED

Inflammatory Bowel Disease

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease

J Crohns Colitis.

Chaparro M, Garre A, Guerra Veloz MF, Vázquez JM, De Castro ML, Leo E, Rodriguez E, Carbajo AY, Riestra S, Jiménez I, Calvet X, Bujanda L, Rivero M, Gomollón F, Benítez JM, Bermejo F, Alcaide N, Gutiérrez A, Mañosa M, Iborra M, Lorente R, Rojas-Feria M, Barreiro-de Acosta M, Kolle L, Van Domselaar M, Amo V, Argüelles F, Ramírez E, Morell A, Bernardo D, Gisbert JP

doi: 10.1093/ecco-jcc/jjz070.

Inflammatory Bowel Disease

Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease

Eur J Gastroenterol Hepatol.

Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL

doi: 10.1097/

Related content

The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches

Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: Short-term experience from a single tertiary clinical center

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort

Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease

Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease